Boundless Bio Appoints Chris Hassig as Its Chief Scientific Officer

Chris Hassig has joined cancer drug developer Boundless Bio as its chief scientific officer. He is tasked with overseeing the San Diego company’s drug discovery efforts, expanding its research team, and guiding the company in building out a pipeline of therapeutics. Hassig was most recently CSO of Sierra Oncology (NASDAQ: [[ticker:SRRA]]); prior he served in a number of roles, including vice president of drug discovery, at the Sanford Burnham Prebys Medical Discovery Institute.

Boundless Bio, which launched with $46 million in September, is developing drugs that target large circles of DNA that are found outside cells’ chromosomes in many solid-tumor cancers.

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine. View all posts by Sarah de Crescenzo